Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).

被引：0
|
作者：
Komrokji, Rami S.
Sekeres, Mikkael A.
Zeidan, Amer Methqal
Fenaux, Pierre
List, Alan F.
Dezern, Amy Elizabeth
Greenberg, Peter L.
Savona, Michael R.
Jurcic, Joseph G.
Verma, Amit
Mufti, Ghulam J.
Buckstein, Rena
Santini, Valeria
Laadem, Abderrahmane
Ito, Rodrigo
Zhang, Jennie
Louis, Chrystal Ursula
Linde, Peter G.
Garcia-Manero, Guillermo
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA
[3] Yale Univ, Yale Sch Med, Dept Internal Med, New Haven, CT USA
[4] Yale Univ, Yale Canc Ctr, Dept Internal Med, New Haven, CT USA
[5] Univ Paris 07, Serv Hematol Seniors, Hop St Louis, Paris, France
[6] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[7] Stanford Univ, Canc Ctr, Stanford, CA 94305 USA
[8] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA
[9] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Div Hematol Oncol, Med Ctr, New York, NY USA
[10] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA
[11] Kings Coll London, Dept Haematooncol, London, England
[12] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[13] Univ Florence, Azienda Osped Univ AOU Careggi, MDS Unit, Florence, Italy
[14] Bristol Myers Squibb, Summit, NJ USA
[15] Acceleron Pharma, Cambridge, MA USA
[16] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7518
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study
    Komrokji, Rami S.
    Platzbecker, Uwe
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Mufti, Ghulam J.
    Santini, Valeria
    Diez-Campelo, Maria
    Finelli, Carlo
    Jurcic, Joseph G.
    Greenberg, Peter L.
    Sekeres, Mikkael A.
    Zeidan, Amer M.
    DeZern, Amy E.
    Savona, Michael R.
    Shetty, Jeevan K.
    Ito, Rodrigo
    Zhang, George
    Ha, Xianwei
    Sinsimer, Daniel
    Backstrom, Jay T.
    Verma, Amit
    BLOOD, 2020, 136
  • [32] Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes ( MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
    Fenaux, Pierre
    Mufti, Ghulam J.
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Finelli, Carlo
    Cazzola, Mario
    Ilhan, Osman
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    List, Alan F.
    Zeidan, Amer M.
    Verma, Amit
    Laadem, Abderrahmane
    Ito, Rodrigo
    Zhang, Jennie
    Rampersad, Anita
    Sinsimer, Daniel
    Linde, Peter G.
    Garcia-Manero, Guillermo
    Platzbecker, Uwe
    BLOOD, 2019, 134
  • [33] Diagnostic Testing Patterns for Ring Sideroblasts (RS) in Patients with Newly Diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Connect® MDS/AML Disease Registry
    Patel, Jay
    Cogle, Christopher
    Foucar, Kathryn
    Grinblatt, David
    Komrokji, Rami
    Savona, Michael
    Scott, Bart
    Sekeres, Mikkael
    Steensma, David
    Flick, Dawn
    Kiselev, Pavel
    Louis, Chrystal
    Nifenecker, Melissa
    Swern, Arlene
    George, Tracy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S343 - S344
  • [34] Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS plus )
    Buckstein, Rena
    Zhu, Nancy
    Keating, Mary-Margaret
    Leber, Brian
    Chodirker, Lisa
    Sabloff, Mitchell
    Cristou, Grace
    Leitch, Heather A.
    St Hilaire, Eve
    Finn, Nicholas
    Yee, Karen W. L.
    Elemary, Mohamed
    Banerji, Versha
    Lenis, Martha
    Kirubananthaan, Aksharh
    Liu, Fei Fei
    Tang, Derek
    Westcott, Chris
    Huang, Vicky Wei-Hsuen
    Wang, Di
    Cameron, Chris
    Morison, Jessica
    Spin, Paul
    Mamedov, Alexandre
    BLOOD, 2019, 134
  • [35] Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
    Platzbecker, Uwe
    Goetze, Katharina S.
    Kiewe, Philipp
    Germing, Ulrich
    Mayer, Karin
    Radsak, Markus
    Wolff, Thomas
    Chromik, Joerg
    Sockel, Katja
    Oelschlaegel, Uta
    Haase, Detlef
    Illmer, Thomas
    Al-Ali, Haifa Kathrin
    Silling, Gerda
    Reynolds, Joseph G.
    Zhang, Xiaosha
    Attie, Kenneth M.
    Shetty, Jeevan K.
    Giagounidis, Aristoteles
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (33) : 3800 - +
  • [36] Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting
    Mukherjee, Sudipto
    Brown-Bickerstaff, Cherrishe
    Falkenstein, Angelica
    Makinde, Adeola Y.
    Bland, Emily
    Laney, JaLyna
    Garretson, Marne Prime
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Luspatercept Reduces Red Blood Cell Transfusions (RBCT) in Patients with Lower-Risk Myelodysplastic Syndromes (LRMDS) Regardless of Baseline Transfusion Burden (TB) in the MEDALIST Study
    Platzbecker, Uwe
    Garcia-Manero, Guillermo
    Fenaux, Pierre
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Tang, Derek
    Ito, Rodrigo
    Fabre, Shannon
    Mantovani, Emily
    Zoffoli, Roberto
    Miteva, Dimana
    Hughes, Christina
    Khan, Wasiulla
    Komrokji, Rami S.
    Germing, Ulrich
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 142 - 142
  • [38] A phase 3, randomized, double-blind study of luspatercept (ACE-536) in patients (pts) with Revised International Prognostic Scoring System (IPSS-R) very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions: The MEDALIST trial.
    Platzbecker, Uwe
    Komrokji, Rami S.
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Mufti, Ghulam J.
    Sekeres, Mikkael A.
    Zhang, Jennie
    Benzohra, Aziz
    Laadem, Abderrahmane
    Vo, Bond
    Attie, Kenneth M.
    List, Alan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ANEMIA REQUIRING TRANSFUSION
    Komrokji, R.
    Garcia-Manero, G.
    Ades, L.
    Laadem, A.
    Vo, B.
    Prebet, T.
    Stamatoullas, A.
    Boyd, T.
    Delaunay, J.
    Steensma, D. P.
    Sekeres, M. A.
    Beyne-Rauzy, O.
    Zou, J.
    Attie, K. M.
    Sherman, M. L.
    Fenaux, P.
    List, A. F.
    HAEMATOLOGICA, 2015, 100 : 192 - 192
  • [40] Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study
    Mittelman, Moshe
    Henry, David H.
    Glaspy, John
    Tombak, Anil
    Harrup, Rosemary Anne
    Madry, Krzysztof
    Grabowska, Barbara
    Platzbecker, Uwe
    Lee, Tyson
    Modelska, Katharina
    BLOOD, 2023, 142
12345